(189 days)
An IV additive dispensing pin for aspiration from single-dose containers with a 20 mm vial closure diameter and a 22mm vial body diameter (6R/8R).
The Mini Spike Plus 6/8 R is an IV additive dispensing pin for aspiration from single-dose containers with the size 6R* or 8R*. It is intended for withdrawal and injection from/in vials. The Mini Spike Plus 6/8 R transfer device is used for the preparation of medications contained in vials with a 20 mm vial closure diameter and a 22mm vial body diameter. The device is for single use and to only be used with single use drug dose vials. The device is configured with a snap cap covering a luer lock female access, a grip plate which features an integrated air filter (0.45 um) and a standard plastic piercing spike. The device provides two separate internal channels: One for injection and withdrawal of fluids, One for the pressure equalization between the vial and the environment. When the device's spike is pierced into a rubber stopper of a drug vial, these channels enable a fluid transfer between a syringe (that is connected with the device's luer connector on the top) and the vial. The vial adapter enables a permanent connection between the Mini Spike Plus 6/8 R and the vial. During the pressure equalization process there is an air exchange with the environment. In order to prevent any contamination of drugs being stored in the vials the air passes a 0.45um bacteria retentive air filter.
The provided text describes a 510(k) premarket notification for a medical device called "Mini Spike Plus 6/8R." This document is for a medical device that does not utilize AI/machine learning. Therefore, the requested information pertaining to AI/ML device performance, such as acceptance criteria for AI models, sample sizes for test sets in AI studies, number of experts for ground truth, adjudication methods, MRMC studies, standalone AI performance, training set details, and ground truth establishment methods, is not applicable to this submission.
The document focuses on demonstrating substantial equivalence to a predicate device (Mini-Spike Plus) based on traditional medical device performance testing and biocompatibility.
Here's the information that is available from the provided text, related to the device's acceptance criteria and studies:
Acceptance Criteria and Device Performance (based on traditional medical device testing):
The document states that the Mini Spike Plus 6/8R device "has met all established acceptance criteria for performance testing and design verification testing." While specific numerical acceptance criteria values are not explicitly presented in a table alongside performance results, the document lists the tests performed, implying that the device passed these tests according to predefined criteria.
Based on the provided text, a table can be constructed to show the types of tests performed, which inherently represent the areas where acceptance criteria were applied. No numerical performance data is given to populate a "Reported Device Performance" column with specific results, only that the device "met all established acceptance criteria."
| Acceptance Criteria Category | Test Performed (Implied Acceptance Criteria) | Reported Device Performance (as stated in the document) |
|---|---|---|
| Functional Performance | ISO 22413:2010: - Particle Contamination - Fragmentation - Air Tightness - Free Flow - Penetration Force - Tensile Load - Visual Inspection - Chemical Analysis ISO 80369-7:2016: - Luer Connector Leakage, Stress Cracking & Resistance Testing - Dimensional Accuracy Internal device performance test methods: - Fluid burst pressure of air filter membrane - Dynamic tensile load between Mini Spike and Vial Adapter | "met all established acceptance criteria for performance testing and design verification testing." |
| Sterile Barrier System | ISO 11607-1: 2006/Amd1:2014, ASTM F 1980-16, ASTM F1886/F1886M-16, ASTM D4169-16, ASTM D4332-14, ASTM F88/F88M-15, ASTM F1929-15, ASTM F2096-11, ASTM F2252/F2252M-13, DIN 58953-6:2016, ISO 11607-2: 2006/Amd:2014: - Sterile Barrier System Validation | "met all established acceptance criteria for performance testing and design verification testing." |
| Microbiological/Contamination | USP <85>, USP <161>: - Bacterial Endotoxin (LAL Gel Clot Test) USP <788>: - Particulate Contamination | "met all established acceptance criteria for performance testing and design verification testing." |
| Biocompatibility | ISO 10993-1:2009 (evaluated according to this standard), performed tests: - Cytotoxicity (ISO 10993-5:2009) - Sensitization (ISO 10993-10:2010) - Intracutaneous Reactivity / Irritation (ISO 10993-10:2010) - Acute Systemic Toxicity (ISO 10993-11:2006) - Hemolysis (ISO 10993-4:2002/Amd1, ASTM F756 (2013)) - Material Mediated Pyrogenicity (ISO 10993-11:2006, USP 38 <151>) | "met all established acceptance criteria for performance testing and design verification testing." |
Information Not Applicable or Not Provided for AI/ML Devices:
- Sample sizes used for the test set and the data provenance: Not applicable. This is a traditional device.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable.
- Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable.
- If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable.
- The type of ground truth used (expert consensus, pathology, outcomes data, etc): Not applicable.
- The sample size for the training set: Not applicable.
- How the ground truth for the training set was established: Not applicable.
Study Proving Device Meets Acceptance Criteria:
The document states: "Functional performance bench testing was conducted to demonstrate that the Mini Spike Plus 6/8R device performs as intended. No clinical testing was performed as this device does not require clinical studies to demonstrate substantial equivalence with the predicate device."
- Type of Study: Bench testing (in vitro mechanical and material testing).
- Reason for no clinical testing: The device's substantial equivalence was demonstrated through bench testing and biocompatibility testing, compared to a legally marketed predicate device with similar intended use and technological characteristics. The differences (primary "new component" being the Vial Adapter and a change in sterilization method) were addressed through specific performance testing to confirm they don't "raise new questions on safety and effectiveness."
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in large, bold, blue letters, and the word "ADMINISTRATION" in smaller, blue letters below.
December 9, 2020
B. Braun Medical Inc. Angela Caravella Sr. Regulatory Affairs Specialist 901 Marcon Boulevard Allentown, Pennsylvania 18109
Re: K201469
Trade/Device Name: Mini Spike Plus 6/8R Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: Class II Product Code: LHI Dated: November 12, 2020 Received: November 13, 2020
Dear Angela Caravella:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
CAPT Alan Stevens Director (acting) DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K201469
Device Name
Mini Spike Plus 6/8R
Indications for Use (Describe)
An IV additive dispensing pin for aspiration from single-dose containers with a 20 mm vial closure diameter and a 22mm vial body diameter (6R/8R).
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
17
{3}------------------------------------------------
510(k) Summary-K201469
1. Submitter Information
| Name: | B. Braun Medical Inc. |
|---|---|
| Address: | 901 Marcon BoulevardAllentown, PA 18109-9341 |
| Contact Person: | Angela J. CaravellaSr. Regulatory Affairs Specialist |
| Telephone Number: | (610) 596 2966 |
| Fax Number: | (610) 266-4962 |
| angela.caravella@bbraunusa.com | |
| Date Prepared: | 09 December 2020 |
2. Device Name and Classification
| Device Trade Name: | Mini Spike Plus 6/8 R |
|---|---|
| Common Name: | Vial Adapter / IV Fluid Transfer Set |
| Classification Name: | Intravascular Administration Set; 21 CFR 880.5440 |
| Regulatory Class | Class II (non-exempt) |
| Product Code: | LHI |
3. Predicate Device
| Device Trade Name: | Mini-Spike Plus |
|---|---|
| Common Name: | Vial Adapter / IV Fluid Transfer Set |
| Classification Name: | Intravascular Administration Set; 21 CFR 880.544c |
| 510(k) Number: | K983794 |
The predicate device 510(k) clearance for K983794 covers three models of the device Mini-Spike Plus. Substantial equivalence is demonstrated with the following two models which are covered by K983794:
- Mini-Spike Plus, #04550242 -
- Chemo Mini-Spike Plus, #412011 -
No reference devices were used in this submission.
{4}------------------------------------------------
4. Device Description
The Mini Spike Plus 6/8 R is an IV additive dispensing pin for aspiration from single-dose containers with the size 6R* or 8R*. It is intended for withdrawal and injection from/in vials.
The Mini Spike Plus 6/8 R transfer device is used for the preparation of medications contained in vials with a 20 mm vial closure diameter and a 22mm vial body diameter. The device is for single use and to only be used with single use drug dose vials.
The device is configured with a snap cap covering a luer lock female access, a grip plate which features an integrated air filter (0.45 um) and a standard plastic piercing spike.
The device provides two separate internal channels:
- One for injection and withdrawal of fluids
- One for the pressure equalization between the vial and the environment
When the device's spike is pierced into a rubber stopper of a drug vial, these channels enable a fluid transfer between a syringe (that is connected with the device's luer connector on the top) and the vial.
The vial adapter enables a permanent connection between the Mini Spike Plus 6/8 R and the vial.
During the pressure equalization process there is an air exchange with the environment. In order to prevent any contamination of drugs being stored in the vials the air passes a 0.45um bacteria retentive air filter.
- The container sizes 6R and 8R are related to the size definitions set out in ISO 8362-1 Injection Containers and accessories-Part 1: Injection vials made of glass tubing.
5. Indications for Use / Intended Use
Indications for Use:
An IV additive dispensing pin for aspiration from single-dose containers with a 20 mm vial closure diameter and a 22mm vial body diameter (6R/8R).
Intended Use:
Withdrawal and injection from/in vials.
{5}------------------------------------------------
6. Substantial Equivalence
Intended Use/Indications for Use - Discussion of differences
The intended use of the proposed and the predicate device are identical. The indications for use of the proposed and the predicate device are equivalent and do not create a new intended use:
- Both devices are intended for aspiration from and injection into vials.
- The proposed device indications for use are limited to vials with a 20 mm vial closure diameter and a 22mm vial body diameter (6R/8R).
- . The indications for use of the proposed device fall within the intended use of the predicate device and, therefore, the two devices have the same intended use. *
The differences in wording of the intended use and indications for use between proposed device and predicate device do not affect safety and effectiveness and do not alter the intended use of the proposed device:
- The indications for use of the proposed device are a subset compared to the predicate ● device indications for use.
- . Both devices are used by the same type of healthcare professionals under the same conditions of use.
- Both devices have an identical principle of operation as well as mechanism of action. ●
- The differences in wording in the indications for use statements do not introduce new ● questions regarding safety or effectiveness due to their similarities in purpose, function and conditions of use.
*Refer to Section IV.D.1. of the Guidance "The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]", issued July 28, 2014.
Technological Characteristics - Discussion of differences
The technological characteristics of the proposed device are substantially equivalent to the predicate device in regards to the technological characteristics as compared in Section 7 below.
Conclusion on Substantial Equivalence
The proposed device Mini Spike Plus 6/8 R has the same intended use and equivalent indications for use as the predicate device. The proposed device has similar technological characteristics to the predicate, and the descriptive and performance information provided within this premarket notification demonstrates that:
- any differences do not raise different questions of safety and effectiveness that the . predicate device; and
- . the proposed device is at least as safe and effective as the legally marketed predicate device.
Based on the comparison of the intended use and the technological characteristics the proposed Mini Spike Plus 6/8 R is substantially equivalent to the currently marketed predicate Mini-Spike Plus.
{6}------------------------------------------------
7. Comparison with Technological Characteristics with the Predicate Device
The technological characteristics of the proposed Mini Spike Plus 6/8 R are substantially equivalent to the predicate Mini-Spike Plus in regards to the following technological characteristics:
- . Principle of operation, mechanism of action and conditions of use are identical between proposed device and predicate device.
- Material Composition is equivalent. Material composition of proposed device does not ● raise new questions of safety and effectiveness, as demonstrated by performance testing and biocompatibility evaluation.
- . Physical Specifications are identical, except the proposed devices new component Vial Adapter. The Vial Adapter does not raise new questions on safety and effectiveness, as demonstrated by performance testing.
- Design Features & Interfaces are identical, except the proposed devices new component ● Vial Adapter. Additional performance verification of the proposed device with Vial Adapter does not raise new questions on safety and effectiveness.
- Sterilization method, SAL Level and sterilization cycle are equivalent between proposed ● device and predicate device. Differences do not raise new questions on safety and effectiveness.
- . Packaging configuration and labeling are equivalent. Differences do not raise new questions on safety and effectiveness.
| Intended Use / Indications for Use Comparison | |||
|---|---|---|---|
| Characteristic | Proposed Device:Mini Spike Plus 6/8 R#4550315-02 | Predicate Device:K983794; Mini-Spike PlusModels:Mini-Spike Plus, #04550242(Model 1)Chemo Mini-Spike Plus,#412011 (Model 2) | Comparison |
| Product Codeand Regulation | LHI21 CFR 880.5440 | LHI21 CFR 880.5440 | Identical |
| Classification | Class II (non-exempt) | Class II (non-exempt) | Identical |
| Review Panel | General Hospital | General Hospital | Identical |
| Type of Use | Prescription use only | Prescription use only | Identical |
| Conditions of Use | Single Use | Single Use | Identical |
| Sterility | Sterile using Ethylene Oxide | Sterile using Gamma Radiation | Equivalent |
| Shelf Life | 5 years | 5 years | Identical |
| Indications for Use | An IV additive dispensing pin foraspiration from single-dosecontainers with the size 6R or 8R. | An IV additive dispensing pin foraspiration from multi-dosecontainers or injection into IVSystems (IV Bags) | Equivalent |
| Intended Use | Withdrawal and injection from/invials. | Withdrawal and injection from/inmultidose vials. | IdenticalLimitations ofindicates for use forproposed device fall |
{7}------------------------------------------------
| Technological Characteristic Comparison | within the intendeduse of the predicatedevice, therefore thetwo devices have thesame intended use. | ||
|---|---|---|---|
| General Characteristics | |||
| Principle ofOperation /Mechanism ofAction | The device provides two separatechannels:- One for injection and withdrawalof fluids- One for the pressure equalizationbetween the vial and theenvironmentWhen the device's spike is piercedinto a rubber stopper of a drug vial,these channels enable a fluidtransfer between a syringe (that isconnected with the device's luerconnector on the top) and the vial. | The device provides two separatechannels:- One for injection and withdrawalof fluids- One for the pressure equalizationbetween the vial and theenvironmentWhen the device's spike is piercedinto a rubber stopper of a drug vial,these channels enable a fluid transferbetween a syringe (that is connectedwith the device's luer connector onthe top) and the vial. | Identical |
| Conditions of Use | Single Use | Single Use | Identical |
| Material Composition | |||
| Grip Piece | Material:SAN/ABS (Styrene-Acrylonitrile /Acrylonitrile-Butadiene-Styrene) | Material:SAN/ABS (Styrene-Acrylonitrile /Acrylonitrile-Butadiene-Styrene) | Identical |
| Piercing Spike | Material:SAN/ABS (Styrene-Acrylonitrile /Acrylonitrile-Butadiene-Styrene) | Material:SAN/ABS (Styrene-Acrylonitrile /Acrylonitrile-Butadiene-Styrene) | Identical |
| Snap Cap | Material:PP (Polypropylene) | Material:PP (Polypropylene) | Identical |
| Air Filter | Material:AVC on PA 6 (Acrylonitrile-Vinylchloride Copolymer onPolyamide) | Material:AVC on PA 6 (Acrylonitrile-Vinylchloride Copolymer onPolyamide) | Identical |
| Protective Cap | N/A for proposed device. | Material:PE-LD (Low-Density Polyethylene) | N/A for proposeddevice. |
| Vial Adapter | Material:Polystyrene | N/A | New component.As demonstrated byperformance testingvial adapter does notraise new questionson safety andeffectiveness. |
| Piercing SpikeLubricant | Material:Silicone Oil | Material:Silicone Oil | Identical |
| Physical Specifications | |||
| Dimensions | Mini Spike(entire device without VialAdapter):Height: 54.7 mmLength: 34 mmWidth: 30 mm | Mini Spike(entire device without ProtectiveCap):Height: 54.7 mmLength: 34 mmWidth: 30 mm | Identical for MiniSpike and PiercingSpikeVial adapterdimensions do notraise questions on |
| Piercing Spike:Length: 21 ± 0.2 mmDiameter: 3.98 +0.2/-0.3 mmVial Adapter:Height: 64 mmLength: 38 mmWidth: 30 mm | Piercing Spike:Length: 21 ± 0.2 mmDiameter: 3.98 +0.2/-0.3 mm | safety andeffectiveness. | |
| Connector Type | Luer Lock | Luer Lock | Identical |
| Color | Snap Cap: GreenGrip Piece & Piercing Spike: WhiteVial Adapter: Transparent | Snap Cap: Green (Model 1)Grip Piece & Piercing Spike: WhiteProtective Cap: Green | Identical(Snap Cap; GripPiece & PiercingSpike) |
| Vial Adapter | Vial adapter keeps proposed deviceconnected to a vial with the size 6Ror 8R. | N/A | Transparent vialadapter does notraise questions onsafety andeffectiveness.New component.As demonstrated byperformance testingvial adapter does notraise new questionson safety andeffectiveness. |
| Design Features & Interfaces | |||
| Luer ConnectorCover | Snap Cap | Snap Cap | Identical |
| Device UserInterface | Grip Piece | Grip Piece | Identical |
| Interface to Syringe | Luer Lock Connector | Luer Lock Connector | Identical |
| Interface to Vial | Piercing spike with dimensions:Length: 21 ± 0.2 mmDiameter: 3.98 +0.2/-0.3 mm | Piercing spike with dimensions:Length: 21 ± 0.2 mmDiameter: 3.98 +0.2/-0.3 mm | Identical |
| Air Filter | 0.45µm | 0.45µm (Model 1) | Identical |
| Protective Cap | N/A for proposed device | Pull Off Cap that prevents piercingof sterile barrier system duringtransport; needs to be removed priorto product usage | FunctionallyEquivalent |
| Vial Adapter | Vial adapter keeps proposed deviceconnected to vial. | N/A | New component.Vial adapter keepsproposed deviceconnected to vial.As demonstrated byperformance testingvial adapter does notraise new questionson safety andeffectiveness |
| Sterilization | |||
| Sterilization Method | Ethylene Oxide | Gamma Radiation | Equivalent |
| Sterility AssuranceLevel (SAL) | 10-6 | 10-6 | sterilizationvalidation thesterilization methoddoes not raise newquestions on safetyand effectivenessIdentical |
| Sterilization Cycle | 90% EO / 10% CO2 | Isotope: Cobalt 60Minimum Dose 18.0 KGyMaximum Dose: 30.0 KGy | EquivalentAs demonstrated bysterilizationvalidation thesterilization methoddoes not raise newquestions on safetyand effectiveness |
| Packaging | |||
| Packaging - SterileBarrier System | Thermoformed film sealed withprinted medical grade paper | Thermoformed film sealed withprinted medical grade paper | EquivalentAs demonstrated bypackaging validationthe packaging doesnot raise newquestions on safetyand effectiveness |
{8}------------------------------------------------
B. Braun Medical Inc.
510(k) Premarket Notification
Mini Spike Plus 6/8 R
{9}------------------------------------------------
8. Performance Testing
Performance Testing Bench
Functional performance bench testing was conducted to demonstrate that the Mini Spike Plus 6/8R device performs as intended. No clinical testing was performed as this device does not require clinical studies to demonstrate substantial equivalence with the predicate device.
{10}------------------------------------------------
B. Braun Medical Inc. 510(k) Premarket Notification Mini Spike Plus 6/8 R
The following performance tests were conducted in support of the substantial equivalence determination:
| Standard | Test Performed |
|---|---|
| ISO 22413:2010 | Particle Contamination Fragmentation Air Tightness Free Flow Penetration Force Tensile Load Visual Inspection Chemical Analysis |
| ISO 80369-7:2016 | Luer Connector Leakage, Stress Cracking & Resistance Testing Dimensional Accuracy |
| ISO 11607-1: 2006/Amd1:2014ASTM F 1980-16ASTM F1886/F1886M-16ASTM D4169-16ASTM D4332-14ASTM F88/F88M-15ASTM F1929-15ASTM F2096-11ASTM F2252/F2252M-13DIN 58953-6:2016ISO 11607-2: 2006/Amd:2014 | Sterile Barrier System Validation |
| USP <85>, USP <161> | Bacterial Endotoxin (LAL Gel Clot Test) |
| Internal device performance test methods | Fluid burst pressure of air filter membrane Dynamic tensile load between Mini Spike and Vial Adapter |
| USP <788> | Particulate Contamination |
{11}------------------------------------------------
Biocompatibility Testing
The final finished Mini Spike Plus 6/8R was evaluated according to ISO 10993-1:2009. The following biocompatibility testing was performed with the reference standard utilized:
| Standard | Test Performed |
|---|---|
| ISO 10993-5:2009 | • Cytotoxicity |
| ISO 10993-10:2010 | • Sensitization• Intracutaneous Reactivity / Irritation |
| ISO 10993-11:2006 | • Acute Systemic Toxicity |
| ISO 10993-4:2002/Amd1ASTM F756 (2013) | • Hemolysis |
| ISO 10993-11:2006USP 38 <151> | • Material Mediated Pyrogenicity |
9. Conclusion
The proposed Mini Spike Plus 6/8R has met all established acceptance criteria for performance testing and design verification testing. Results of functional performance and biocompatibility testing conducted with the Mini Spike Plus 6/8R device demonstrate that the proposed device supports a substantial equivalence determination to the predicate device as described in Section 6.
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.